Teladoc Health, Inc. Investigation
Company: Teladoc Health, Inc.
Ticker: (NYSE) TDOC
Join the Teladoc Health, Inc. Investigation
Investigation Details
Teladoc Health shares dropped more than 28% after the Company reported second quarter 2026 consolidated revenue of $606.9 million -- below the consensus range of $615 million to $628 million -- and lowered its full-year 2026 revenue outlook to $2.36 billion to $2.45 billion.
On February 25, 2026, Teledoc issued revenue guidance of $2.47 billion to $2.59 billion, and further specifically projected a revenue decline for the BetterHelp division of 7% to 0.5%. During the Company’s Q1 report on April 29, 2026, both of these ranges were narrowed, with revenue guidance updated to a range of approximately $2.48 billion to $2.57 billion and BetterHelp projected to decline 6.5% to 1% for the full year.
On the Company's July 29, 2025 earnings call, Teladoc CEO, Charles Divita, noted that the “BetterHelp revenue growth outlook provided with our first quarter results assumed we would achieve the dual goals of scaling insurance, while at the same time stabiliizing and growing overall BetterHelp segment revenues.” He further disclosed that the “decline in cash pay users … accelerated beyond the decline incorporated in our prior outlook” and insurance capacity “did not expand at the same pace as the increase in demand.”